References
- Liamis G, Rodenburg EM, Hofman A, et al. Electrolyte disorders in community subjects: prevalence and risk factors. Am J Med. 2013;126:256–263.
- Filippatos TD, Elisaf MS. Hyponatremia in patients with heart failure. World J Cardiol. 2013;5:317–328.
- Filippatos TD, Liamis G, Christopoulou F, et al. Ten common pitfalls in the evaluation of patients with hyponatremia. Eur J Intern Med. 2016; 29:22–25..
- Gankam Kengne F, Andres C, Sattar L, et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM. 2008;101:583–588.
- Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:71 e1–8.
- Hoorn EJ, Rivadeneira F, Van Meurs JB, et al. Mild hyponatremia as a risk factor for fractures: the Rotterdam Study. J Bone Miner Res. 2011;26:1822–1828.
- Hoorn EJ, Liamis G, Zietse R, et al. Hyponatremia and bone: an emerging relationship. Nat Rev Endocrinol. 2012;8:33–39.
- Snell DM, Bartley C. Osmotic demyelination syndrome following rapid correction of hyponatraemia. Anaesthesia. 2008;63:92–95.
- Tavare AN, Murray D. Central pontine myelinolysis. N Engl J Med. 2016;374:e8.
- Singh TD, Fugate JE, Rabinstein AA. Central pontine and extrapontine myelinolysis: a systematic review. Eur J Neurol. 2014;21:1443–1450.
- Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126:S1–S42.
- Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant. 2014;29(Suppl 2):i1–i39.
- Liamis G, Milionis HJ, Elisaf M. Endocrine disorders: causes of hyponatremia not to neglect. Ann Med. 2011;43:179–187.
- Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52:144–153.
- Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med. 1992;117:891–897.
- Adrogue HJ, Madias NE. Diagnosis and treatment of hyponatremia. Am J Kidney Dis. 2014;64:681–684.
- Liamis G, Elisaf M. Treatment of hyponatremia: what the clinician needs to know. J Nephrol Res. 2015;1:19–21.
- Pallavi R. An unsuspected cause of hyponatremia: beer potomania. J Am Geriatr Soc. 2015;63:1714–1715.
- Srisung W, Mankongpaisarnrung C, Anaele C, et al. A rare case of low-solute hyponatremia in a nonalcoholic person. Case Rep Nephrol Dial. 2015;5:49–53.
- Thaler SM, Teitelbaum I, Berl T. “Beer potomania” in non-beer drinkers: effect of low dietary solute intake. Am J Kidney Dis. 1998;31:1028–1031.
- Berl T, Rastegar A. A patient with severe hyponatremia and hypokalemia: osmotic demyelination following potassium repletion. Am J Kidney Dis. 2010;55:742–748.
- Dellabarca C, Servilla KS, Hart B, et al. Osmotic myelinolysis following chronic hyponatremia corrected at an overall rate consistent with current recommendations. Int Urol Nephrol. 2005;37:171–173.
- Lohr JW. Osmotic demyelination syndrome following correction of hyponatremia: association with hypokalemia. Am J Med. 1994;96:408–413.
- Mohmand HK, Issa D, Ahmad Z, et al. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol. 2007;2:1110–1117.
- Liamis G, Kalogirou M, Saugos V, et al. Therapeutic approach in patients with dysnatraemias. Nephrol Dial Transplant. 2006;21:1564–1569.
- Rose B. Hypoosmolal states – hyponatremia. In: Clinical physiology of acid-base and electrolyte disorders. 4th ed. New York (NY): McGraw-Hill; 1994. p. 651–694.
- Duggal A, Yadav P, Agarwal A, et al. Clinical approach to altered serum sodium levels. JIACM. 2006;7:91–103.
- Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–1589.
- Liamis G, Filippatos TD, Elisaf MS. Correction of hypovolemia with crystalloid fluids: individualizing infusion therapy. Postgrad Med. 2015;127:405–412.
- Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356:2064–2072.
- Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am. 2003;32:459–481. vii.
- Hwang KS, Kim G-H. Thiazide-induced hyponatremia. Electrolyte Blood Press. 2010;8:51–57.
- Liamis G, Elisaf M. Syndrome of inappropriate antidiuresis associated with multiple sclerosis. J Neurol Sci. 2000;172:38–40.
- Milionis HJ, Liamis GL, Elisaf MS. The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ. 2002;166:1056–1062.
- Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170:G1–G47.
- Shoker AS. Application of the clearance concept to hyponatremic and hypernatremic disorders: a phenomenological analysis. Clin Chem. 1994;40:1220–1227.
- Furst H, Kr H, Post J, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci. 2000;319:240–244.
- Sterns RH, Silver SM, Hix JK. Urea for hyponatremia? Kidney Int. 2015;87:268–270.
- Gankam Kengne F, Couturier BS, Soupart A, et al. Urea minimizes brain complications following rapid correction of chronic hyponatremia compared with vasopressin antagonist or hypertonic saline. Kidney Int. 2015;87:323–331.
- De Las Penas R, Ponce S, Henao F, et al. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan. Support Care Cancer. 2016;24:499–507.
- Tzoulis P, Waung JA, Bagkeris E, et al. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion. Clin Endocrinol (Oxf). 2016; 84:620–626.
- Petereit C, Zaba O, Teber I, et al. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm Med. 2013;13:55.
- Adrogue HJ, Madias NE. Aiding fluid prescription for the dysnatremias. Intensive Care Med. 1997;23:309–316.
- Barsoum NR, Levine BS. Current prescriptions for the correction of hyponatraemia and hypernatraemia: are they too simple? Nephrol Dial Transplant. 2002;17:1176–1180.
- Adrogue HJ, Madias NE. The challenge of hyponatremia. J Am Soc Nephrol. 2012;23:1140–1148.
- Sood L, Sterns RH, Hix JK, et al. Hypertonic saline and desmopressin: a simple strategy for safe correction of severe hyponatremia. Am J Kidney Dis. 2013;61:571–578.
- Rose B, Post T. Clinical physiology of acid-base and electrolyte disorders. 5th ed. New York (NY): McGraw-Hill; 2001.
- Abraham WT, Decaux G, Josiassen RC, et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int. 2012;82:1215–1222.
- Liamis G, Filippatos TD, Elisaf MS. Treatment of hyponatremia: the role of lixivaptan. Expert Rev Clin Pharmacol. 2014;7:431–441.
- Lehrich RW, Ortiz-Melo DI, Patel MB, et al. Role of vaptans in the management of hyponatremia. Am J Kidney Dis. 2013;62:364–376.
- Greenberg A, Verbalis JG, Amin AN, et al. Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int. 2015;88:167–177.
- Fukui H. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites? World J Gastroenterol. 2015;21:11584–11596.
- Kogiso T, Tokushige K, Hashimoto E, et al. Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis. Hepatol Res. 2016;46:E194–E200.
- Yan L, Xie F, Lu J, et al. The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2015;15:65.
- Tolvaptan summary of product characteristics. [ cited 2015 Oct 24]. Available from: http://www.otsukapharma.info/medical-professionals/samsca/pdf/Samsca15mg-SPC-Eng-201108.pdf.
- Tolvaptan prescribing information. [ cited 2015 Oct 24]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022275s009lbl.pdf.
- Watkins PB, Lewis JH, Kaplowitz N, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38:1103–1113.
- Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–2418.
- Tolvaptan-FDA drug safety communication. [ cited 2015 Oct 24]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350185.htm.
- Palmer BF, Rock AD, Woodward EJ. Dose comparison of conivaptan (Vaprisol(R)) in patients with euvolemic or hypervolemic hyponatremia – efficacy, safety, and pharmacokinetics. Drug Des Devel Ther. 2016;10:339–351.
- Dominguez M, Perez JA, Patel CB. Efficacy of 3% saline vs. conivaptan in achieving hyponatremia treatment goals. Methodist Debakey Cardiovasc J. 2013;9:49–53.
- Conivaptan summary of product characteristics [Internet; cited 2015 Oct 24]. Available from: http://www.vaprisol.com/pdf/Vaprisol-PI-Apr2015.pdf.
- Sterns RH, Hix JK. Overcorrection of hyponatremia is a medical emergency. Kidney Int. 2009;76:587–589.
- Perianayagam A, Sterns RH, Silver SM, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol. 2008;3:331–336.